AWTAD

pahomepage | March 17, 2020

We’re seeing events being canceled left and right to encourage social distancing during the fight against COVID-19. Some of these events are fundraising efforts that keep non-profits afloat. “Whether or not we’re having fundraisers, when that pager goes off, we’re going,” said Dave Truskowsky, president of West End Fire and Rescue. In times of emergencies, volunteer fire companies like West End Fire and Rescue in Mahanoy City are always there to answer the call. &ld...

Nonprofit Technology

Network for Good | January 05, 2022

The social good software platform backed by funds advised by Apax Partners LLP and formed through the combination of CyberGrants, EveryAction, and Social Solutions, announced that it has reached an agreement to acquire Network for Good, a Certified B Corporation and leading provider of cloud-based fundraising software for nonprofits. Terms of the transaction were not disclosed. Network for Good, which will be the first acquisition for the recently formed Company, helps small and m...

Nonprofit Technology, Philanthropy

Silent Donor | October 06, 2022

Silent Donor has publicly launched their online service that provides an easy, accessible way for donors to send anonymous donations to established nonprofit or charitable 501(c)(3) organizations. They are the first online donation platform designed from the ground up to protect the privacy of donors. "Growing numbers of individuals and companies, for a variety of reasons, want to carry out their charitable giving anonymously, Our platform offers the privacy and...

GSK | January 27, 2020

GlaxoSmithKline has licensed a tuberculosis vaccine to the Bill & Melinda Gates Medical Research Institute (MRI). The deal sets the stage for a push to build on recent phase 2b data and make the vaccine available in low-income countries where TB is prevalent. The vaccine, M72/AS01E, is made up of an immunogenic fusion protein based on two TB antigens. GSK combined that protein with the adjuvant found in its shingles prophylactic Shingrix to create a subunit vaccine. Last year, a phase 2b tri...